Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Defining the immunogenic landscape of early mosquito-stage P. falciparum to accelerate malaria transmission-blocking vaccine discovery

Award Number: R01AI183678
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/05/2024
PERIOD OF PERFORMANCE END DATE: 05/31/2029

Group Awards By:

View Award Description

Defining the immunogenic landscape of early mosquito-stage P. falciparum to accelerate malaria transmission-blocking vaccine discovery - PROJECT SUMMARY The disease malaria is caused by vector-borne parasites of the genus Plasmodium. With hundreds of millions of infections and over half a million deaths annually, malaria remains one of the foremost global health challenges. The two WHO-recommended malaria vaccines have only moderate efficacy against severe disease and do not provide sterilizing protection, neither do they prevent transmission of the parasite to the mosquito vector that carries it between human hosts. The majority of vaccine development efforts to date have focused on means to prevent infection of humans. However, a comprehensive malaria eradication effort also requires blocking transmission with vector-targeted interventions. Compared with vaccines that prevent infection by targeting pre- erythrocytic and asexual blood stages of the parasite, very few candidate antigens have been identified for transmission-blocking vaccines (TBVs) that target the transmitted forms of the parasite present in the mosquito vector stages. This disparity arises in part because the comprehensive characterization of protein expression that informs vaccines against pre-erythrocytic and asexual blood stages has not been performed for the stages that develop in the mosquito midgut, i.e., gametes, zygotes, and ookinetes. The few TBV candidates that have entered clinical trials, including Pfs25, Pfs48/45, and Pfs230, are surface-exposed on these early mosquito-stage parasites. Importantly, it has been demonstrated that antibodies against these proteins can be generated in the vertebrate host, carried to the mosquito vector in the blood meal, and subsequently interfere with fertilization and/or successful infection of the mosquito. We hypothesize that early mosquito-stage parasites exhibit many more undiscovered surface-exposed proteins, and that these proteins can be targeted by antibodies to prevent transmission of the malaria parasite to the mosquito vector. We will use mass spectrometry-based proteomics to provide the first comprehensive catalog of surface-exposed proteins in P. falciparum gametes, zygotes, and ookinetes. In parallel, we will immunize animals with early mosquito-stage parasites and identify parasite proteins that elicit an immune response. From the subset of immunogenic surface-exposed parasite proteins, we will identify the most promising TBV candidates and evaluate them as antigens for transmission-blocking vaccines by quantifying the ability of antibodies against these antigens to prevent P. falciparum from infecting mosquitoes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $947,948 )
2025	2025	INSTITUTE FOR SYSTEMS BIOLOGY	401 TERRY AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	2	5/21/2025	NON-COMPETING CONTINUATION	$947,948
														Subtotal = $947,948

Issue Date FY: 2024 ( Subtotal = $969,948 )
2024	2024	INSTITUTE FOR SYSTEMS BIOLOGY	401 TERRY AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	1	7/5/2024	NEW	$875,155
2024	2024	INSTITUTE FOR SYSTEMS BIOLOGY	401 TERRY AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	1	9/4/2024	NEW	$94,793
														Subtotal = $969,948

Grand Total All Awards = $1,917,896

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Defining the immunogenic landscape of early mosquito-stage P. falciparum to accelerate malaria transmission-blocking vaccine discovery

Award Number: R01AI183678

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/05/2024

PERIOD OF PERFORMANCE END DATE: 05/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer